Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Restructuring Costs (2021 - 2023)

Theravance Biopharma (TBPH) has disclosed Restructuring Costs for 3 consecutive years, with $1.2 million as the latest value for Q2 2023.

  • Quarterly Restructuring Costs fell 61.03% to $1.2 million in Q2 2023 from the year-ago period, while the trailing twelve-month figure was $2.7 million through Dec 2023, down 93.95% year-over-year, with the annual reading at $2.7 million for FY2023, 78.63% down from the prior year.
  • Restructuring Costs for Q2 2023 was $1.2 million at Theravance Biopharma, down from $1.6 million in the prior quarter.
  • The five-year high for Restructuring Costs was $33.0 million in Q3 2022, with the low at $38000.0 in Q4 2022.
  • Average Restructuring Costs over 3 years is $10.2 million, with a median of $6.2 million recorded in 2022.
  • Peak annual rise in Restructuring Costs hit 114.29% in 2022, while the deepest fall reached 99.79% in 2022.
  • Over 3 years, Restructuring Costs stood at $18.3 million in 2021, then plummeted by 99.79% to $38000.0 in 2022, then skyrocketed by 2976.32% to $1.2 million in 2023.
  • According to Business Quant data, Restructuring Costs over the past three periods came in at $1.2 million, $1.6 million, and $38000.0 for Q2 2023, Q1 2023, and Q4 2022 respectively.